Thomas Fekete, MD, MACP, Thomas Durant Chair and Professor of Medicine and Professor of Microbiology and Immunology at the Lewis Katz School of Medicine at Temple University, offered insight to WHYY about Merck’s new drug molnupiravir, which could be the first pill to treat COVID-19. Merck has asked the U.S. Food and Drug Administration to authorize the treatment.
IMPORTANT: Beginning at 8:00 AM on September 3, Temple University Hospital – Main Campus (Broad and Ontario Streets) will no longer provide Labor and Delivery services. All childbirth services will be relocated to our new hospital location.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH
Related News
Dr. Anjali Vaidya Participates in Q&A with Healio on Novel Screening Tool Developed at Lewis Katz School of Medicine Which Shows Significant Promise for Improving Detection of Pulmonary Arterial Hypertension
Posted July 24, 2025Anjali Vaidya, MD, FACC, FASE, FACP, Director of the Advanced Pulmonary Hypertension, Right Heart Failure & Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program at Temple University Hospital, participated in a Q&A interview with Healio.
Read MoreDr. Ahmed Sadek Provides Perspective for Medscape Article on Report Analyzing PAH Incidence, Mortality Rates at National, Regional and Global Level
Posted July 24, 2025Ahmed S. Sadek, MD, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University, provided perspective for a Medscape article on a report published in Frontiers in Public Health in which researchers analyzed data on pulmonary arterial hypertension (PAH).
Read More